Lifeward Q2 Revenue Jumps 16% on ReWalk Exoskeleton Strength
LFWD sits 81% above its 52-week low of $4.14.
Summary
Lifeward's Q2 revenue rose 16% year-over-year to $6.62 million, driven by a 13% increase in ReWalk Personal exoskeleton sales (mainly Europe) and a 25% rise in AlterG product and service revenue in the U.S. Adjusted net loss widened to $4.10 million ($1.46 per share) from higher clinical trial expenses, while gross margin fell to 41% from 44% due to tariffs, FX, and a 4% revenue sharing expense from the Oramed transaction. The company launched a pilot with Ottobock Care to expand U.S. access to its exoskeleton and expects revenue momentum to continue in H2 2026. This follows the Q2 loss report earlier today and the July convertible financing; the revenue growth and distribution expansion are new details that add a positive operational angle to an otherwise cash-burning story.
At the time of this announcement, LFWD was trading at $7.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.3M. The 52-week trading range was $4.14 to $10.56. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.